136 related articles for article (PubMed ID: 8981483)
1. Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist.
Hirst RA; Almond SL; Lambert DG
Neurosci Lett; 1996 Dec; 220(2):101-4. PubMed ID: 8981483
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine.
Ross RA; Brockie HC; Fernando SR; Saha B; Razdan RK; Pertwee RG
Br J Pharmacol; 1998 Nov; 125(6):1345-51. PubMed ID: 9863666
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A.
Petitet F; Marin L; Doble A
Neuroreport; 1996 Feb; 7(3):789-92. PubMed ID: 8733746
[TBL] [Abstract][Full Text] [Related]
4. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development.
Yang ZM; Paria BC; Dey SK
Biol Reprod; 1996 Oct; 55(4):756-61. PubMed ID: 8879486
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.
Rinaldi-Carmona M; Barth F; Héaulme M; Alonso R; Shire D; Congy C; Soubrié P; Brelière JC; Le Fur G
Life Sci; 1995; 56(23-24):1941-7. PubMed ID: 7776817
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum.
Griffin G; Wray EJ; Martin BR; Abood ME
Br J Pharmacol; 1999 Oct; 128(3):684-8. PubMed ID: 10516649
[TBL] [Abstract][Full Text] [Related]
7. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
Smith SR; Terminelli C; Denhardt G
J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163
[TBL] [Abstract][Full Text] [Related]
8. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Héaulme M; Shire D; Calandra B; Congy C; Martinez S; Maruani J; Néliat G; Caput D
FEBS Lett; 1994 Aug; 350(2-3):240-4. PubMed ID: 8070571
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments.
Yousif MH; Oriowo MA
Pharmacol Res; 1999 Nov; 40(5):415-21. PubMed ID: 10527656
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain.
Kathmann M; Bauer U; Schlicker E; Göthert M
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):466-70. PubMed ID: 10431757
[TBL] [Abstract][Full Text] [Related]
11. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
Petitet F; Jeantaud B; Capet M; Doble A
Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum.
Devlin MG; Christopoulos A
J Neurochem; 2002 Mar; 80(6):1095-102. PubMed ID: 11953460
[TBL] [Abstract][Full Text] [Related]
13. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus.
Coutts AA; Pertwee RG
Br J Pharmacol; 1997 Aug; 121(8):1557-66. PubMed ID: 9283688
[TBL] [Abstract][Full Text] [Related]
14. A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis.
Gross A; Terraza A; Marchant J; Bouaboula M; Ouahrani-Bettache S; Liautard JP; Casellas P; Dornand J
J Leukoc Biol; 2000 Mar; 67(3):335-44. PubMed ID: 10733093
[TBL] [Abstract][Full Text] [Related]
15. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
16. Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.
De Vry J; Jentzsch KR
Behav Pharmacol; 2004 Feb; 15(1):13-20. PubMed ID: 15075622
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
18. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands.
Smith SR; Terminelli C; Denhardt G
Eur J Pharmacol; 2001 Aug; 425(1):73-83. PubMed ID: 11672577
[TBL] [Abstract][Full Text] [Related]
19. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
Rinaldi-Carmona M; Pialot F; Congy C; Redon E; Barth F; Bachy A; Brelière JC; Soubrié P; Le Fur G
Life Sci; 1996; 58(15):1239-47. PubMed ID: 8614277
[TBL] [Abstract][Full Text] [Related]
20. Regional differences in cannabinoid receptor/G-protein coupling in rat brain.
Breivogel CS; Sim LJ; Childers SR
J Pharmacol Exp Ther; 1997 Sep; 282(3):1632-42. PubMed ID: 9316881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
